MDS (low and INT-1 risk as per the IPSS for MDS)
Showing 1 - 25 of >10,000
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
- Oral Azacitidine
- Placebo for Oral Azacitidine
-
Buenos Aires, Argentina
- +1 more
Aug 1, 2022
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston
Recruiting
- Chronic Myelomonocytic Leukemia
- +5 more
- Canakinumab
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
MDS, Thrombocytopenia Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Eltrombopag)
Completed
- Myelodysplastic Syndromes
- Thrombocytopenia
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 8, 2022
Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)
Active, not recruiting
- Myelodysplastic Syndrome (MDS)
- sabatolimab
- +2 more
-
Brasschaat, Belgium
- +9 more
Jan 19, 2023
AML, MDS, Old Age; Debility Trial in Suzhou (Azacitidine, all trans retinoic acid)
Recruiting
- AML
- +3 more
- Azacitidine
- all trans retinoic acid
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 27, 2021
Anemia Trial (Luspatercept)
Not yet recruiting
- Anemia
- Luspatercept
- (no location specified)
May 26, 2023
Low Risk MDS Trial (R906289 Monosodium (R289 Na))
Not yet recruiting
- Low Risk Myelodysplastic Syndromes
- R906289 Monosodium (R289 Na)
- (no location specified)
Jul 22, 2022
MDS Trial in Beijing (Hetrombopag, Stanozolol Tablets)
Not yet recruiting
- MDS
- Hetrombopag
- Stanozolol Tablets
-
Beijing, ChinaPeking Union Medical College Hospital
Sep 18, 2021
Anemia, MDS Trial in Germany (Canakinumab Injection)
Recruiting
- Anemia
- Myelodysplastic Syndromes
- Canakinumab Injection
-
Berlin, Germany
- +5 more
Nov 8, 2022
MDS Trial in Houston (Sertraline, Bone Marrow Aspirate/Biopsy)
Terminated
- Myelodysplastic Syndromes
- Sertraline
- Bone Marrow Aspirate/Biopsy
-
Houston, Texas
- +1 more
May 31, 2022
MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)
Active, not recruiting
- Myelodysplastic Syndromes
- MBG453
- +2 more
-
Duarte, California
- +46 more
Jan 20, 2023
MDS Trial in France, Germany (N-Plate / romiplostim)
Completed
- Myelodysplastic Syndromes
- N-Plate / romiplostim
-
Annecy, France
- +35 more
Sep 7, 2021
MDS Trial in Worldwide (Talacotuzumab, Daratumumab)
Completed
- Myelodysplastic Syndromes
-
Saint Louis, Missouri
- +20 more
Dec 28, 2022
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,
Active, not recruiting
- High Risk Myelodysplastic Syndrome
- +2 more
- Azacitidine
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
MDS (MDS) Trial in United Kingdom (Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol)
Recruiting
- Myelodysplastic Syndromes (MDS)
- Sodium Valproate, Bezafibrate, Medroxyprogesterone
- Danazol
-
Dudley, England, United Kingdom
- +7 more
Aug 12, 2022
MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)
Not yet recruiting
- Myelodysplastic Syndromes
- Luspatercept
- Epoetin Alfa
-
Concord, California
- +100 more
Jul 20, 2023
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts) Trial in Worldwide (FG-4592, Placebo)
Active, not recruiting
- Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
- Roxadustat
- Placebo
-
Los Angeles, California
- +71 more
Sep 16, 2022